| Press releases

Formycon CEO Dr. Carsten Brockmeyer once again honored as one of the world’s most influential people in the medicines industry

Dr. Carsten Brockmeyer, CEO of Formycon AG, has again been chosen as one of the world’s top 100 most influential people in the pharmaceutical sector by the trade magazine “The Medicine Maker”

Calendar

German Equity Forum 2016

German Equity Forum 2016, November 21 – 23; Frankfurt/Main

Financial reports
hjb_teaser_2015@2x

Half-Year Report 2015

Published on 14. September 2015

  • buchner_en
  • pipeline-en-teaser
  • slider03
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.